Skip to main content

AZZ

Stock
Industrials
Specialty Business Services

Performance overview

AZZ Price
Price Chart

Forward-looking statistics

Beta
0.68
Risk
34.45%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. In its Metal Coatings segment, the company offers metal finishing services to protect against corrosion, such as hot dip galvanizing, spin galvanizing, powder coating, anodizing, and plating. The Precoat Metals Segment offers aesthetic and corrosion-resistant coatings for steel and aluminum coils.

Company info

SectorIndustrials
IndustrySpecialty Business Services
Employees2K
Market cap$2.3B

Fundamentals

Enterprise value$3.7B
Revenue$1.6B
Revenue per employee—
Profit margin8.17%
Debt to equity84.12

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$1.79
Dividend per share$0.68
Revenue per share$54.24
Avg trading volume (30 day)$22M
Avg trading volume (10 day)$32M
Put-call ratio—

Macro factor sensitivity

Growth+1.6
Credit+4.4
Liquidity+0.6
Inflation-1.1
Commodities-0.7
Interest Rates-2.1

Valuation

Dividend yield0.68%
PEG Ratio17.63
Price to sales1.89
P/E Ratio17.63
Enterprise Value to Revenue2.35
Price to book2.85

Upcoming events

Next earnings dayApril 22, 2025
Next dividend day—
Ex. dividend dayJuly 10, 2025

News

AZZ (AZZ) Q1 Earnings Beat Estimates

AZZ (AZZ) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.46 per share a year ago.

Zacks Investment Research (July 9, 2025)
Is JAZZ Stock Undervalued At $110?

Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aimed at advanced HER2-Positive Biliary Tract Cancer. Ziihera is the first HER2-targeted therapy approved in the EU for this condition, with anticipated peak annual sales surpassing $2 billion.

Forbes (July 7, 2025)
AZZ Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

AZZ Inc. AZZ will release earnings results for the first quarter, after the closing bell on Wednesday, July 9.

Benzinga (July 2, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free